These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22563239)

  • 41. Tocilizumab: Another medication related to osteonecrosis of the jaws? A case report and literature review.
    Sakkas A; Heil S; Kargus S; Rebel M; Mischkowski RA; Thiele OC
    GMS Interdiscip Plast Reconstr Surg DGPW; 2021; 10():Doc03. PubMed ID: 33928006
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
    Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC
    Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis.
    Mori S; Urata Y; Yoshitama T; Ueki Y
    RMD Open; 2021 May; 7(2):. PubMed ID: 33958440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
    Frey N; Grange S; Woodworth T
    J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
    Dehoratius RJ; Brent LH; Curtis JR; Ellis LA; Tang KL
    Patient; 2018 Jun; 11(3):361-369. PubMed ID: 29427176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model.
    Hashemi-Meshkini A; Nikfar S; Glaser E; Jamshidi A; Hosseini SA
    Value Health Reg Issues; 2016 May; 9():42-48. PubMed ID: 27881258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
    Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
    Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis].
    Willeke P; Becker H; Wassenberg S; Pavenstädt H; Jacobi AM
    Z Rheumatol; 2011 Apr; 70(3):232-4, 236-8. PubMed ID: 21359555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of general practice nursing care on patient satisfaction and enablement in Australia: A mixed methods study.
    Desborough J; Bagheri N; Banfield M; Mills J; Phillips C; Korda R
    Int J Nurs Stud; 2016 Dec; 64():108-119. PubMed ID: 27768985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.
    Dhillon S
    BioDrugs; 2014 Feb; 28(1):75-106. PubMed ID: 24255004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient and health professional satisfaction with an interdisciplinary patient safety program.
    Ruiz-Millo O; Climente-Martí M; Navarro-Sanz JR
    Int J Clin Pharm; 2018 Jun; 40(3):635-641. PubMed ID: 29594676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.
    Balsa A; Tovar Beltrán JV; Cáliz Cáliz R; Mateo Bernardo I; García-Vicuña R; Rodríguez-Gómez M; Belmonte Serrano MA; Marras C; Loza Cortina E; Pérez-Pampin E; Vila V
    Rheumatol Int; 2015 Sep; 35(9):1525-34. PubMed ID: 25773655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
    de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB
    Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
    Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
    Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis.
    Yazici Y; McMorris BJ; Darkow T; Rosenblatt LC
    Clin Exp Rheumatol; 2009; 27(6):907-13. PubMed ID: 20149304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis.
    Leroy M; Coiffier G; Pronier C; Triquet L; Perdriger A; Guggenbuhl P
    Joint Bone Spine; 2015 Jul; 82(4):278-9. PubMed ID: 25791259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Building a sustainable rural physician workforce.
    Ostini R; McGrail MR; Kondalsamy-Chennakesavan S; Hill P; O'Sullivan B; Selvey LA; Eley DS; Adegbija O; Boyle FM; Dettrick Z; Jennaway M; Strasser S
    Med J Aust; 2021 Jul; 215 Suppl 1():S5-S33. PubMed ID: 34218436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.